Mantha S, Laube E, Miao Y et al.. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 2017;43:166–171.
Raskob GE, van Es N, Verhamme P et al.. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615–624.
Young A, Marshall A, Thirlwall J et al.. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D pilot trial [abstract]. Blood 2017;130:Abstract 625.
Lee AY, Levine MN, Baker RI et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–153.
Smrke A, Gross PL. Cancer-associated venous thromboembolism: a practical review beyond low-molecular-weight heparins. Front Med (Lausanne) 2017;4:142.
Noble S, Prout H, Nelson A. Patients' xperiences of living with cancer-associated thrombosis: the PELICAN study. Patient Prefer Adherence 2015;9:337–345.
Khorana AA, McCrae KR, Milentijevic D et al.. Current practice patterns and patient persistence with anticoagulant treatments for cancer–associated thrombosis. Res Pract Thromb Haemost 2017;1:14–22.